RedX Pharma ploughs calmly ahead with advanced treatments in a torrid market

RedX Pharma ploughs calmly ahead with advanced treatments in a torrid market

‘The important thing is the fundamentals of the business are incredibly strong. We need to maximise the value that we can secure from the portfolio. After that the share price takes care of itself.’

The words are those of Redx Pharma chief executive Neil Murray and they reveal a steely resolve.

Some might view the slide in the Redx share price as suggestive of a struggling company. But nothing really could be further from the truth.

Read the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.